Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
Theravance Biopharma, Inc. (TBPH) Debt to Equity Ratio data is not available for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$64.38M |
|
$-56.42M |
|
-- |
|
$64.38M |
|
$111.33M |
|
$-46.95M |
|
$2.33M |
|
$-44.61M |
|
$-44.61M |
|
$-56.42M |
|
$-56.42M |
|
$-56.42M |
|
$-56.42M |
|
$-46.95M |
|
$-47.75M |
|
48.85M |
|
48.85M |
|
$-1.15 |
|
$-1.15 |
|
| Balance Sheet Financials | |
$161.07M |
|
$7.42M |
|
$193.09M |
|
$354.16M |
|
$32.09M |
|
-- |
|
$146.53M |
|
$178.62M |
|
$175.55M |
|
$175.54M |
|
$175.54M |
|
49.47M |
|
| Cash Flow Statement Financials | |
$-11.54M |
|
$12.28M |
|
$-2.50M |
|
$40.38M |
|
$38.63M |
|
$-1.75M |
|
$21.39M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.02 |
|
-- |
|
-- |
|
-- |
|
|
Debt to Equity Ratio |
-- |
100.00% |
|
-72.92% |
|
-72.92% |
|
-74.16% |
|
-69.30% |
|
-87.63% |
|
$-11.87M |
|
-- |
|
-- |
|
-- |
|
0.18 |
|
-- |
|
0.94 |
|
388.01 |
|
-32.14% |
|
-32.14% |
|
-15.93% |
|
-32.14% |
|
$3.55 |
|
$-0.24 |
|
$-0.24 |
|